Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 191 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tociliuzumab Clear all

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 10
States / cities: Birmingham, Alabama • Fresno, California • Jacksonville, Florida + 6 more

Conditions: Non-Hodgkin Lymphoma
Interventions: Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine, Oxaliplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Duarte, California • Chesterfield, Missouri • Austin, Texas + 1 more

Conditions: Advanced Liver Cancers
Interventions: Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Tocilizumab, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 16
States / cities: Costa Mesa, California • Duarte, California • Orange, California + 11 more

Conditions: Melanoma
Interventions: Ipilimumab, Nivolumab, Tocilizumab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York

Conditions: Hematologic Malignancy, Bone Marrow Transplant
Interventions: Tocilizumab, Fludarabine, Melphalan, Anti-thymocyte globulin (rabbit), Total Body Irradiation; Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Covid19, Urine, Biomarker, Acute Respiratory Failure With Hypoxia
Interventions: Not listed
Lead sponsor: National Center for Global Health and Medicine, Japan; Government
Eligibility: 20 Years and older
Enrollment: 964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-Hodgkin's Lymphoma
Interventions: Glofitamab, Obinutuzumab, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 6
States / cities: Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 2 more

Conditions: Arthritis, Juvenile Rheumatoid, Still's Disease, Juvenile Onset
Interventions: tocilizumab; Biological
Lead sponsor: Tufts Medical Center; Other
Eligibility: 2 Years to 16 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Castleman's Disease
Interventions: tocilizumab [RoActemra/Actemra]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Small Cell Lung Cancer, Neuroendocrine Carcinoma
Interventions: RO7616789, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Detroit, Michigan + 7 more

Conditions: Cholangiocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma
Interventions: TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab; Biological · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2042
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia
Interventions: Alemtuzumab, Etoposide, Dexamethasone, Methotrexate, Phone Call, Tocilizumab; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Juvenile Idiopathic Arthritis
Interventions: Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Up to 24 Months
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Louisville, Kentucky + 5 more

Conditions: COVID-19 Pneumonia
Interventions: Tociliuzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 24
States / cities: Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Tocilizumab, Venetoclax; Biological · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acute Graft Versus Host Disease
Interventions: Tocilizumab; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Giant Cell Arteritis
Interventions: Tocilizumab, Prednisone, Tocilizumab Placebo, Prednisone Placebo, Corticosteroids, Methotrexate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 14
States / cities: Los Angeles, California • Boca Raton, Florida • Sarasota, Florida + 10 more

Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)
Interventions: Linvoseltamab, Tocilizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Los Angeles, California • St. Petersburg, Florida • Baton Rouge, Louisiana + 4 more

Conditions: Solid Tumors
Interventions: RO6958688, Obinutuzumab, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • Santa Monica, California + 6 more

Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
Interventions: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 890 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 78
States / cities: Tuscaloosa, Alabama • Peoria, Arizona • Scottsdale, Arizona + 68 more

Conditions: Breast Cancer
Interventions: Trastuzumab, Pertuzumab, Tocilizumab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Chicago, Illinois • Ann Arbor, Michigan • New Haven, New York

Conditions: CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions: Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate, Tocilizumab; Biological · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: Tocilizumab; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 30 Years to 60 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Risk Stratification of COVID-19 Using Urine Biomarkers

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis

A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

TCR1188-ABC Cells in KRAS-mutated Cancers

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder